| Parkinson Disease
Nourianz vs Ongentys
Side-by-side clinical, coverage, and cost comparison for parkinson disease.Deep comparison between: Nourianz vs Ongentys with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOngentys has a higher rate of injection site reactions vs Nourianz based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ongentys but not Nourianz, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Nourianz
Ongentys
At A Glance
Oral
Daily
Adenosine A2A receptor antagonist
Oral
Daily
COMT inhibitor
Indications
- Parkinson Disease
- Parkinson Disease
Dosing
Parkinson Disease 20 mg orally once daily; may increase to 40 mg once daily based on individual need and tolerability; may be taken with or without food; max 20 mg once daily with strong CYP3A4 inhibitors or moderate hepatic impairment; 40 mg once daily in tobacco smokers (>=20 cigarettes/day); avoid with strong CYP3A4 inducers or in severe hepatic impairment.
Parkinson Disease 50 mg orally once daily at bedtime; avoid food 1 hour before and at least 1 hour after dose; reduce to 25 mg in moderate hepatic impairment (Child-Pugh B); avoid use in severe hepatic impairment (Child-Pugh C).
Contraindications
—
- Concomitant use of non-selective monoamine oxidase (MAO) inhibitors
- Pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms
Adverse Reactions
Most common (>=5%) Dyskinesia, dizziness, constipation, nausea, hallucination, insomnia
Serious Dyskinesia, hallucinations/psychotic behavior, impulse control/compulsive behaviors
Postmarketing Increased libido
Most common (>=4%) Dyskinesia, constipation, blood creatine kinase increased, hypotension/syncope, weight decreased
Serious Cardiovascular effects with COMT-metabolized drugs, falling asleep during activities of daily living, hypotension/syncope, dyskinesia, hallucinations and psychosis, impulse control/compulsive disorders, withdrawal-emergent hyperpyrexia and confusion
Postmarketing Fall
Pharmacology
Adenosine A2A receptor antagonist; istradefylline is a xanthine derivative demonstrated in vitro and in animal studies to block adenosine A2A receptors, though the precise mechanism of therapeutic action in Parkinson's disease is unknown.
Opicapone is a peripheral, selective and reversible inhibitor of catechol-O-methyltransferase (COMT) that reduces levodopa breakdown to 3-OMD, thereby increasing levodopa exposure in Parkinson's disease patients treated with levodopa/carbidopa.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Nourianz
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Ongentys
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Nourianz
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Ongentys
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (2/8) · Qty limit (1/8)
Humana
Nourianz
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Ongentys
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$20/fillfill
Nourianz Copay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Ongentys.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NourianzView full Nourianz profile
OngentysView full Ongentys profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.